For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...
The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results